OPZELURA — Total revenues
Incyte OPZELURA — Total revenues decreased by 31.0% to $143.02M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 20.5%, from $118.71M to $143.02M. Over 3 years (FY 2022 to FY 2025), OPZELURA — Total revenues shows an upward trend with a 74.0% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates growing market penetration, successful commercialization, or expansion into new therapeutic indications, while a decrease may signal increased competition, patent expirations, or declining demand.
Detailed definition
This metric represents the total gross revenue generated from the sale of a specific pharmaceutical product or therapeut...
Peer comparison
Comparable to product-specific revenue reporting in other biopharmaceutical firms, often benchmarked against peak sales estimates and market share within specific therapeutic classes.
incy_segment_opzelura_total_revenuesHistorical Data
| Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $4.67M | $12.75M | $16.56M | $38.14M | $61.28M | $56.55M | $80.23M | $91.84M | $109.24M | $85.72M | $121.70M | $139.27M | $161.60M | $118.71M | $164.50M | $187.97M | $207.28M | $143.02M |
| QoQ Change | — | — | +173.2% | +29.8% | +130.3% | +60.7% | -7.7% | +41.9% | +14.5% | +19.0% | -21.5% | +42.0% | +14.4% | +16.0% | -26.5% | +38.6% | +14.3% | +10.3% | -31.0% |
| YoY Change | — | — | — | — | — | >999% | +343.4% | +384.5% | +140.8% | +78.3% | +51.6% | +51.7% | +51.7% | +47.9% | +38.5% | +35.2% | +35.0% | +28.3% | +20.5% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Incyte's opzelura — total revenues?
- Incyte (INCY) reported opzelura — total revenues of $143.02M in Q1 2026.
- How has Incyte's opzelura — total revenues changed year-over-year?
- Incyte's opzelura — total revenues increased by 20.5% year-over-year, from $118.71M to $143.02M.
- What is the long-term trend for Incyte's opzelura — total revenues?
- Over 3 years (2022 to 2025), Incyte's opzelura — total revenues has grown at a 74.0% compound annual growth rate (CAGR), from $128.74M to $678.46M.
- What does opzelura — total revenues mean?
- The total amount of money earned from sales of a specific drug product.